News

Stay Up-To-Date on NEXT Oncology

  • All
  • NEXT Oncology Blog
  • NEXT Oncology News
  • Press Releases

Bright Peak Therapeutics Announces Formation of World Class Immuno-Oncology Scientific Advisory Board

Internationally renowned researchers Gordon Freeman, Ph.D., Thomas Gajewski, M.D., Ph.D., Jason Luke, M.D., Ignacio Melero, M.D., Ph.D., and Anthony Tolcher, M.D., to advise Bright Peak in its mission to develop …

NEXT Oncology Selects proXimityTM to Automate Data Transfer for Clinical Trials

System will accelerate performance evaluation of new drugs in early phase research for cancer patients. (SAN ANTONIO) October 17, 2022 –– NEXT Oncology has selected proXimityTM as the exclusive tool …

Approach for Early Stage HER 2 Neu Positive Breast Cancer

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …

Research shows that cancer death rates are dropping across the country

AN ANTONIO – Cancer death rates are dropping across the country, according to the American Association for Cancer Research. There are more than 18 million cancer survivors in the U.S., …

NEXT Oncology’s Dr. Anthony Tolcher Presents Data on Well-Tolerated Monotherapy
for Advanced and Metastatic Tumors at ESMO Congress 2022

DCC-3116 is a first-in-class inhibitor of autophagy. (SAN ANTONIO) September 16, 2022 –– Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, returned from the European Society for Medical Oncology …

Alexander I. Spira, MD, PhD, FACP, Provides an Overview of the Use of Adagrasib in Advanced KRAS G12C–Mutant NSCLC at ASCO 2022

In an interview with CancerNetwork® during the 2022 American Society of Clinical Oncology Annual Meeting, Alexander I. Spira, MD, PhD, FACP, a medical oncologist and co-director of the Virginia Cancer Specialists Research …

DCC-3116 Acceptable Treatment in RAS/RAF-Mutant Solid Tumors

A phase 1/2 trial (NCT04892017) found a potential treatment with DCC-3116 monotherapy given between 50 mg to 300 mg twice daily for patients with RAS or RAF-mutant solid tumors, based …

Sometimes less is more: Reviewing axillary management studies in upfront surgery for patients with early breast cancer stages.

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …

Long-term Outcomes of Adjuvant Denosumab in Breast Cancer: Fracture reduction and Survival of 3,425 patients in the randomized, double blind, placebo controlled ABCSG-18 trial.

Research remains an essential part of cancer care. In this blog, we will provide information about recent updates or new approvals as it applies to breast cancer written by Dr. …

Qualigen Therapeutics Announces Formation and First Meeting of QN-302 Scientific Advisory Board

CARLSBAD, Calif., Aug. 18, 2022 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for …